1Hjalmarson A,Goldstein S,Fagerberg B,et al.Effects of controlled-release metoprolol on total mortality,hospitalizations,and well-being in patients with heart failure:the metoprolol CR/XL randomized intervention trial in congestive heart failure(MERIT-HF)[J].JAMA,2000,283(10):1295-1302.
3Guzzetti S,La Rovere MT,Pinna GD,et al.Different spectral components of 24 h heart rate variability are related to different modes of death in chronic heart failure[J].Eur Heart J,2005,26(4):357-362.
6Swedberg K,Cleland J,Dargie H,et al.Guidelines for the diagnosis and treatment of chronic heart failure;executive summary(update 2005):the task force for the diagnosis and treatment of chronic heart failure of the european society of cardiology[J].Eur Heart J,2005,26(11):1115-1140.
二级参考文献11
1CIBIS-II Investigatiors, Conunittes. The cardiac insufficiency bisoprolol study IICIBIS-II. Lancet, 1999,353:9-13.
2ME RIT-HF Study Group. Effect or metoprolol CRIXL in chronic heart failure;Metoprolol CR1 XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 1999, 353: 2001-2007.
3Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and morbidity in patients with chronic heart failure. N Engl J Med, 1996,334 : 1349-1355.
6Packer M,coats AIS, Fowler MB, et al. Effect of carvedilol on sur- vival in severe chronic heart failure. N EnglJ Med, 2001,344: 1651-1658.
7Brat BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction; results from the SPICE Registry. Eur Heart J, 1999,20 : 1182-1190.
